|
Volumn 101, Issue 2, 2003, Pages 118-120
|
Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)
a a |
Author keywords
Mycobacterium w; Non small cell lung cancer; Quality of life
|
Indexed keywords
CISPLATIN;
ETOPOSIDE;
IMMUNOMODULATING AGENT;
IMMUVAC;
UNCLASSIFIED DRUG;
BACTERIAL VACCINE;
IMMUNOLOGICAL ADJUVANT;
ADULT;
ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CHRONOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG TOLERABILITY;
ERYTHEMA;
FEMALE;
HUMAN;
IMMUNOMODULATION;
INJECTION PAIN;
LUNG NON SMALL CELL CANCER;
MALE;
MYCOBACTERIUM;
PROGNOSIS;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
SEQUENTIAL ANALYSIS;
SEQUENTIAL CHEMOTHERAPY;
SKIN INDURATION;
TIME SERIES ANALYSIS;
TUMOR REGRESSION;
TUMOR VOLUME;
ADOLESCENT;
AGED;
IMMUNOLOGY;
IMMUNOTHERAPY;
LUNG TUMOR;
METHODOLOGY;
MIDDLE AGED;
TREATMENT OUTCOME;
ADJUVANTS, IMMUNOLOGIC;
ADOLESCENT;
ADULT;
AGED;
BACTERIAL VACCINES;
CARCINOMA, NON-SMALL-CELL LUNG;
CISPLATIN;
ETOPOSIDE;
FEMALE;
HUMANS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
MYCOBACTERIUM;
QUALITY OF LIFE;
TREATMENT OUTCOME;
|
EID: 0043270342
PISSN: 00195847
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (25)
|
References (4)
|